Novo Nordisk's Balancing Act: Legal Wins and Raised Guidance Against a Stalled Pipeline
Published on 08/09/2026 at 08:21 | Redaktion boerse-global.de
The past week has handed Novo Nordisk a study in contrasts. The Danish pharmaceutical giant posted better-than-expected quarterly results and lifted its full-year outlook, secured a court injunction against a Dutch pharmacy chain selling unapproved copycat GLP-1 products, and yet still finds itself wrestling with a failed late-stage trial and billions in writedowns. The net effect on the share price? A Friday rally that traders struggled to pin on any single catalyst.
A Forecast That Points Both Ways
The numbers delivered on Tuesday painted a picture of operational resilience. Second-quarter revenue rose 7 percent on a currency-adjusted basis, while adjusted operating profit climbed 11 percent. That momentum prompted management to narrow its full-year guidance: instead of the previously flagged 4 to 12 percent decline in currency-adjusted sales and operating profit, Novo now expects a range from flat to a 6 percent drop, citing stronger expectations for its GLP-1 franchise.
The oral version of Wegovy, launched in January, generated 3.22 billion Danish kroner in second-quarter sales — marginally shy of the 3.27 billion kroner analysts had penciled in. Still, the company says more than five million prescriptions have been written since launch, and the pill claims a 90 percent share of the US oral obesity market. Those figures, alongside a patient base that has grown to 46 million people with obesity or diabetes — five million of whom are on an obesity therapy, up 70 percent year-on-year — provide the counterweight to the pipeline disappointments that have weighed on sentiment.
The ZEUS Setback and Its Cost
The encouraging core metrics, however, sit alongside a substantial drag. Novo booked non-cash impairment charges of 6.3 billion kroner on intangible pipeline assets, with 4.0 billion kroner attributed to the drug candidate Monlunabant. The writedowns trace back in part to the failure of the Phase 3 ZEUS trial for Ziltivekimab, announced in late July. The placebo-controlled, double-blind study, which enrolled more than 6,300 patients with atherosclerosis, chronic kidney disease, and elevated inflammatory markers, missed its primary endpoint of reducing major cardiovascular events — despite demonstrating the expected target engagement and inhibition of the IL-6 signaling pathway.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Two further cardiovascular studies, HERMES and ARTEMIS, will continue, with readouts not expected before the first half of 2027. Management stresses that the ZEUS outcome does not alter the communicated 2026 guidance, though it will trigger another non-cash impairment in the third quarter.
CEO Maziar Doustdar acknowledged the company has absorbed "some setbacks in research and development," pointing explicitly to the failed Ziltivekimab trial, and reiterated a strategy of pursuing complementary acquisitions to bolster the pipeline. CFO Karsten Munk Knudsen was blunter regarding the Inversago acquisition, conceding the business had not developed as hoped and that all activities inherited from the deal have now been wound down.
A Legal Victory in the Compounding Fight
On the intellectual property front, Novo secured a win in the Netherlands. A Dutch court granted a preliminary injunction against Ceban Ziekenhuisfarmacie, a pharmacy chain that had been manufacturing and distributing an unapproved semaglutide nasal spray. The ruling bars production and sales in the country, marking a notable success in the company's broader campaign against compounding pharmacies that market replicas of patented GLP-1 drugs.
What Drove Friday's Move?
The share price response to this mixed news flow has been characteristically volatile. On Friday, the stock advanced 2.69 percent to close at €40.99 in German trading, though no specific company announcement appeared to trigger the move. Mads Zink, chief trader at Danske Bank, attributed the rally to three factors: a broadly firm tone across European pharma stocks, a reassessment of the prior decline as an overreaction, and a combination of reinforcing elements. Since Tuesday's earnings release, the shares have gained 6.6 percent; even the disappointing Ziltivekimab data, which emerged on Thursday, failed to derail the recovery, with the stock up 2.7 percent since then.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The bigger picture remains sobering. The stock sits roughly a quarter below its 52-week high of €54.86 set in January and is down 6.88 percent on the year. An analysis by the Danish newspaper Jyllands-Posten calculates that Novo has shed around 3,000 billion Danish kroner in market capitalization from its peak, though the paper argues the broader Danish economy remains largely insulated from that decline. Chart-wise, the shares are trading almost exactly at their 50-day moving average — a technically neutral position that reflects the market's unresolved verdict on a company delivering strong commercial execution while its research pipeline stumbles. The buyback program, meanwhile, continues apace: through August 3, Novo had repurchased more than 27 million B-shares at an average price of 278.35 kroner, for a total outlay exceeding 15 billion kroner.
The coming months will test whether the commercial engine can continue to outrun the pipeline's disappointments — and whether the legal victory in the Netherlands signals a broader tightening of the noose around copycat manufacturers. For now, investors appear to be weighing the raised guidance more heavily than the writedowns, though the stock's distance from its highs suggests the jury is still out.
Ad
Novo Nordisk Stock: New Analysis - 9 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
